SciSparc Ltd.
SPRC
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement wā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.46
Price-3.95%
-$0.06
1Y
Price
Market Cap
$760.006k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1703.5%
EBITDA Margin-2023.4%
Net Profit Margin-403.7%
Free Cash Flow MarginRevenue
$2.674m
+104.8%
1y CAGR+54.6%
3y CAGR+47.5%
5y CAGREarnings
-$17.854m
-184.1%
1y CAGR-101.5%
3y CAGR-62.3%
5y CAGREPS
-$45.22
-4087.0%
1y CAGR-1328.6%
3y CAGR-976.5%
5y CAGRBook Value
-$81k
$5.139m
Assets$5.220m
Liabilities$2.452m
DebtDebt to Assets
47.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$9.619m
-88.5%
1y CAGR-7.1%
3y CAGR-43.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company